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tion costs, region, health conditions, and treatment pat-
terns) that may influence schizophrenia-related costs and
total costs. Estimation was conducted via a two-stage in-
strumental variable model. RESULTS: The mean unad-
justed total schizophrenia-related cost per patient per
year was $4,973, and the total unadjusted health care
cost per patient per year was $7,335. Although the daily
drug costs associated with olanzapine were higher than
risperidone, and patients taking olanzapine on average
stayed on therapy longer than those taking risperidone,
when looking at total schizophrenia-related costs (ser-
vices plus prescription utilization), there was no signifi-
cant difference between drug groups (olanzapine $81
lower, p  0.7534). Additionally, when total health care
costs were analyzed, there was no significant difference in
drug groups (olanzapine $530 lower, p  0.1050). Sensi-
tivity analyses found similar results. CONCLUSION:
This naturalistic study used data from a Texas Medicaid
population to examine the schizophrenia-related costs
(and total costs) for patients who received olanzapine
versus risperidone. No differences in direct costs were
found for patients receiving olanzapine versus risperi-
done.
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Newer antidepressants are often prescribed to geriatric
patients with depression because older agents often have
side effects that may be problematic in the elderly. Less
well-understood are the prescribing patterns of clinicians
when such first-line agents are switched or augmented.
OBJECTIVE: To examine switching and augmentation
patterns used during the inpatient and post-discharge pe-
riod in geriatric patients with major depression (ICD-9-
CM codes 296.20-296.36) treated initially with fluoxe-
tine, mirtazapine, sertraline, or venlaxafine. METHOD:
Data were obtained from the CQISM Outcomes Mea-
surement System, an ORYX (JCAHO) accepted perfor-
mance improvement system, which tracked patients ad-
mitted to geropsychiatric inpatient programs in 111
general hospitals across 33 states between 1997–1999. A
Medication Usage Questionnaire was used to track medi-
cations prescribed just prior to admission, at time of dis-
charge, and at three-month post-discharge follow-up.
RESULTS: From admission to discharge, over one-third
to one-half (37.4–52.1%) of patients switched or aug-
mented specific antidepressant agent. Switching and aug-
menting rates decreased somewhat from discharge to fol-
low-up (10.5–29.6%) and from admission to follow-up
(30.5–38.9%). Remarkably, over twenty distinct antide-
pressant agents were used when switching occurred, and
fifteen distinct antidepressant agents were used to aug-
ment the initial antidepressant agent. CONCLUSIONS:
A significant number of patients do not appear to im-
prove adequately on their agent of first choice. The great
variety of treatment combinations suggests there is no
clearly preferred treatment strategy for partial and non-
responders. Practice guidelines for treatment strategies to
augment and switch in older patients with depression
would be beneficial for both clinicians and patients.
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OBJECTIVES: This study sought to: 1) analyze trends in
utilization of antidepressant and antipsychotic medica-
tions in Medicaid between 1995 and 1999; 2) gauge
the utilization and diffusion of new generation, branded
antidepressants and antipsychotics during this period.
METHODS: The study was based on a time-series analy-
sis of quarterly, state-level, Medicaid pharmaceutical
claims, as administered by HCFA. Data from 45 states
were suitable for analysis. RESULTS: In 1998, antide-
pressants and antipsychotics accounted for 9% of Medic-
aid prescriptions, but 19% of expenditures. From 1995
to 1998, Medicaid prescriptions for antidepressant and
antipsychotic medications grew by 40% and 20%, re-
spectively; corresponding expenditures grew by 96% and
160%. The growth rate in both prescriptions and expen-
ditures for antidepressants and antipsychotics outpaces
that observed in Medicaid pharmacy benefits as a whole
by more than two-fold. In 1995, new generation antide-
pressants and antipsychotics accounted for 44% and
17.5% of all prescriptions for Medicaid antidepressants
and antipsychotics, respectively. By 1998, these new gen-
eration drugs had accounted for 62% and 51% of all
Medicaid prescriptions for antidepressants and antipsy-
chotics. CONCLUSIONS: Antidepressants and antipsy-
chotics account for a large proportion of Medicaid phar-
maceutical prescriptions and reimbursements. The total
Medicaid market for antidepressants and antipsychotics
grew dramatically over this four-year period. The impact
of newer antidepressants and antipsychotics on expendi-
tures is disproportionate to the number of prescriptions
for these agents. New generation antidepressants and an-
tipsychotics have been accepted into common use within
Medicaid programs. Increased Medicaid expenditures for
antidepressants have been driven both by the uptake of
new generation agents and by increased overall prescrip-
tion volume. Increased Medicaid expenditures for anti-
psychotics have been driven by increased utilization of
atypical antipsychotics. Utilization of new-generation an-
tidepressants and antipsychotics varies among the states;
not all states have adopted new generation agents as
quickly as others.
